Downstream of c-KIT, MK-2206 and ipatasertib/GDC-0068 are potent and highly selective pan-AKT inhibitors, and both are currently in multiple phase 2 trials (clinicaltrials.gov NCT01802320, NCT02162719, NCT01776008), including treatment of ovarian cancer (NCT01283035). The gene discussed is AKT1; the disease is ovarian carcinoma.